Comparative Pharmacology
Head-to-head clinical analysis: BUTICAPS versus NEMBUTAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTICAPS versus NEMBUTAL.
BUTICAPS vs NEMBUTAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butalbital, a barbiturate, acts as a GABA-A receptor agonist, enhancing inhibitory neurotransmission in the CNS; acetaminophen inhibits cyclooxygenase (COX) activity and modulates endogenous cannabinoid receptors; caffeine is a non-selective adenosine receptor antagonist.
Barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and neuronal hyperpolarization. At high doses, has direct inhibitory effects on excitatory AMPA and kainate receptors.
500 mg orally every 8 hours.
Induction of anesthesia: 50-120 mg IV as a single dose. Maintenance of anesthesia: additional doses of 20-40 mg IV as needed. For sedation (preoperative): 100-200 mg IM or 1-5 mg/kg IV 1-1.5 hours before procedure. For status epilepticus: loading dose of 5-15 mg/kg IV slow push, then 1-5 mg/kg/h IV infusion.
None Documented
None Documented
3-5 hours (prolonged in renal impairment; dose adjustment required for CrCl <30 mL/min)
Terminal elimination half-life is 40-120 hours (mean ~80 hours). The prolonged half-life contributes to accumulation with repeated dosing and residual sedation.
Renal (90% as unchanged drug), biliary/fecal (10%)
Renal elimination of unchanged drug accounts for approximately 30-35% of a dose; the remainder is hepatically metabolized. Less than 5% is excreted unchanged in feces.
Category C
Category C
Barbiturate
Barbiturate